Opthea Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Fred Guerard

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	24.9%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Fred Guerard's beloning veranderd ten opzichte van Opthea's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	US$1m	US$373k	-US$220m

Compensatie versus markt: De totale vergoeding ($USD 1.50M ) Fred } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 1.10M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Fred te vergelijken met de prestaties van het bedrijf.

CEO

Fred Guerard (52 yo)

1.1yrs

Tenure

US$1,496,440

Compensatie

Dr. Frederic Guerard, also known as Fred, Pharm. D., M.S., is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at LENZ Therapeutics, Inc. since September 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Frederic Guerard	Chief Executive Officer	1.1yrs	US$1.50m	geen gegevens
Megan Baldwin	Founder	no data	US$1.36m	0.016% A$ 159.1k
Karen Adams	VP of Finance & Company Secretary	3.4yrs	US$466.17k	0% A$ 0
Thomas Reilly	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Kevin Bitter	VP of Strategy & Corporate Development	no data	geen gegevens	geen gegevens
Anand Sundaram	Vice President Marketing	less than a year	geen gegevens	geen gegevens
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	geen gegevens	geen gegevens
Julie Clark	Senior Vice President of Clinical Development	less than a year	geen gegevens	geen gegevens
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	geen gegevens	geen gegevens
Jen Watts	VP Global Clinical Operations	less than a year	geen gegevens	geen gegevens
Dayong Li	Senior VP	less than a year	geen gegevens	geen gegevens
Mike Campbell	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

0.5yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OPT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Megan Baldwin	Founder	no data	US$1.36m	0.016% A$ 159.1k
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	geen gegevens	geen gegevens
Jeremy Levin	Chairperson	4.1yrs	US$309.43k	0.0051% A$ 51.4k
Jason Slakter	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Quinton Oswald	Independence Non-Executive Director	2.6yrs	US$135.81k	geen gegevens
Julia Haller	Independent Non-Executive Director	3.4yrs	US$170.25k	geen gegevens
Lawrence Gozlan	Independent Non-Executive Director	4.3yrs	US$790.52k	0.15% A$ 1.5m
Sujal Shah	Independent Non-Executive Director	less than a year	US$16.72k	geen gegevens
Anshul Thakral	Non-Executive Director	1.4yrs	US$103.72k	geen gegevens
Charles Wykoff	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Susan Orr	Independent Non-Executive Director	2.6yrs	US$130.26k	geen gegevens
Timothy Jackson	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OPT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Opthea Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Opthea Limited Announces Executive Changes

Opthea Limited Announces Board Appointments

Less than half of directors are independent

Opthea Limited Announces Board Changes

Recent updates

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Price target increased by 16% to AU$0.91

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 30%, EPS upgraded

Opthea Limited Announces Executive Changes

New minor risk - Profitability

Full year 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 10% to AU$0.79

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer